(600721)"XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 600721 · · 10 pages · Chinese
Summary by 6ix AI
The report indicates a substantial decrease in revenue and net profit, attributed to reduced business volume and increased competition in the pharmaceutical sector. The company also reported that some bank funds are currently under judicial preservation due to legal disputes involving its subsidiaries, but this has not materially affected operations.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Xinjiang Baihuacun Pharam Tech Co. Ltd. on 6ix
Earlier from Xinjiang Baihuacun Pharam Tech
- XINJIANG BAI HUA CUN PHARMA TECH CO., LTD.: Announcement on Completion of the Industrial and Commercial Registration Change and Issuance of a New Business License
- XINJIANG BAI HUA CUN PHARMA TECH CO., LTD.: Announcement on Appointment of Board Secretary
- XINJIANG BAI HUA CUN PHARMA TECH CO., LTD.: Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- XINJIANG BAI HUA CUN PHARMA TECH CO., LTD.: Continuous Supervision Opinion for Q2 2026 of GUOTAI HAITONG SECURITIES CO., LTD. on the Detailed Report on Change in Equity Interests of XINJIANG BAI HUA CUN PHARMA TECH CO., LTD.
- XINJIANG BAI HUA CUN PHARMA TECH CO., LTD.: Announcement on Shareholding Reduction Plan of Shareholder
Later from Xinjiang Baihuacun Pharam Tech
All Xinjiang Baihuacun Pharam Tech news releasesFollow Xinjiang Baihuacun Pharam Tech into a list and get an email when it puts out news.
Follow Xinjiang Baihuacun Pharam Tech